Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Althaus

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Rhinology. Supplement|July 24, 2010
4-Phase-Rhinomanometry (4PR)--basics and practice 2010Klaus Vogt, Alfredo A Jalowayski, W Althaus, et al.
Biochemical Pharmacology|March 22, 1996
The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptaseI W Althaus, K C Chou, R J Lemay, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Journal of Medicinal Chemistry|August 5, 2016
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor FamilyJeff B Smaill, Andrea J Gonzales, Julie A Spicer, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Rhinology. Supplement|July 24, 2010
4-Phase-Rhinomanometry (4PR)--basics and practice 2010Klaus Vogt, Alfredo A Jalowayski, W Althaus, et al.
Biochemical Pharmacology|March 22, 1996
The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptaseI W Althaus, K C Chou, R J Lemay, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Journal of Medicinal Chemistry|August 5, 2016
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor FamilyJeff B Smaill, Andrea J Gonzales, Julie A Spicer, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Pageof 4